In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
Telaprevir in Combination with a Long-Acting Interferon and Ribavirin Will Earn Decision Resources' Clinical Gold Standard for Hepatitis C Virus in 2012, According to a New Report from Decision Resources
WALTHAM, Mass., March 18 /PRNewswire/ -- Decision Resources, one of the world's leading r...
Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
Editorial Accompanies Manuscript in March Issue
TAMPA, Fla., March 2 /PRNewswire/ -- A study evaluating nitazoxanide in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection with genotype 4 was published in the March issue of Gastroen...
Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
- In this Cohort of Nucleoside-Naive Chronic Hepatitis B e-Antigen (HBeAg) Positive Patients, Resistance Monitoring Identified One Patient with Genotypic Resistance to BARACLUDE -
BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company
(NYSE: BMY ) today announc...
Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir
...epatitis C virus," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "Nearly all surveyed physicians said that improvements in sustained virologic
response in genotype 1-infected patients is the most important endpoint that will persuade them to use a novel treatment in place of currently-availab...
Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments
... ZALBIN met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a). With half the injections, ZALBIN achieved a rate of sustained virologic
response comparable to Pegasys in these studies, with rates of serious and/or severe adverse events that also were comparable. ZALBIN is being develo...
96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy
...ed likelihood of treatment response.
In patients who have experienced virologic
failure on an NNRTI-containing regimen, do not use INTELENCE in combination...chieved an undetectable viral load (<50 copies/mL) at week 48 maintained virologic
suppression through week 96 vs. 88 percent of patients in the placebo arm. ...
New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies
...e were no statistically significant differences in virologic
response rates between treatment-experienced women...pare the percentages of women and men who achieved virologic
response, defined as a viral load of <50 copies... treatment discontinuations for reasons other than virologic
failure were censored (non-VF censored-TLOVR), 73 ...
Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
...ading adjunct candidate based on outcomes of a recent phase II study, which documented that 51% of patients that previously failed SOC had a sustained virologic
response (SVR) when retreated with SOC and Teleprevir in combination. When considering that only 14% of patients in the study control arm responded to...
New treatment option for patients with chronic hepatitis C
...rate, 31.6 percent, was observed in noncirrhotic patients who had a partial virologic
response with a greater than 2-log10 decline in HCV RNA during their previo...tment in the present study was observed in F0-F3 patients who had a partial virologic
response during their prior course of treatment."
PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
...ric subjects 6 to <18 years of age and weighing at least 44 lbs (20 kg). virologic
response rate was evaluated at week 24.
response was defined as a decrease in plasma HIV-1 RNA viral load of at lea...
Virologic in Medical Technology
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of
treatment with R7128 1500mg and Pegasys(R) plus Copegus(R) with safety and tolerability comparable to placebo - - Conference Call Scheduled for 4:00PM ET Today -
PRINCETON, N.J., Jan. 7 /PRNew...
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Top Line Results of Phase II Study in Previous Nonresponders also Reported
KENILWORTH, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today provided an update on the clinical
development program for boceprevir, its investigational oral hepatitis C
New Clinical Study Results Indicate Higher Early Virologic Response
with Celgosivir Combination Therapy in HCV Non-Responders
Data to be Presented April 15th at EASL Conference in Barcelona,
VANCOUVER and SAN DIEGO, CA, April 11, 2007
/PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer
of drugs for infectious diseases, has received new top-line results
confirming the previously announced clinical res...
TMC125 Showed Significant Virologic Response at Week 24 in
Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3
Data Published in The Lancet on TMC125, an Investigational NNRTI
YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from two
ongoing Phase 3 studies (DUET-1 and DUET-2) showed significantly
more HIV-1 adult patients with documented non-nucleoside reverse
transcriptase inhibitor (NNRTI) ...
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
...g have not been established. All study participants also received tenofovir and emtricitabine (Truvada(R)).
The study's primary endpoint was virologic
response at 48 weeks of treatment, with response defined as a viral load of <50 copies/mL measured at two consecutive visits prior to week 48 (i.e....
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... while having the additional benefit of preserving the current first-line therapy and subsequent regimens for future use."
In the study, the virologic
benefit of vicriviroc administered once-daily as a single 30 mg tablet in combination with ritonavir-boosted atazanavir(2) is being compared to a cont...
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
...with undetectable virus at week 12 (complete early virologic
response), received treatment for 48 weeks (n=816)...tients were treated.
In this study, sustained virologic
response (SVR)(3) with 72-week treatment was not s...ent for 24 or 48 weeks and maintaining a Sustained virologic
Response (SVR) 24 weeks after the last dose. (2) P...
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
...on of pegylated interferon plus ribavirin, which delivers overall sustained virologic
response rates (SVR) of 50-60 percent.
"These are exciting times in ou...R7227/ITMN-191) Inhibitor Combination in HCV: Safety, Pharmacokinetics, and virologic
Results from INFORM-1," Abstract #1046: to be presented at 44th Annual Meet...
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
...2b) met the primary efficacy endpoint of sustained virologic
response comparable to Pegasys (peginterferon alfa... half the injections, achieved a rate of sustained virologic
response comparable to Pegasys," said David C. Stu...erferon alfa-2b treatment group achieved sustained virologic
response (SVR), vs. 51.0% (225/441) in the peginte...
Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
...this study triggered a $10 million payment to Pharmasset from Roche.
A Phase I/IIa trial demonstrated the ability of R7128 to generate high rapid virologic
response rates (RVR) in combination with PEGASYS and COPEGUS. Unlike protease inhibitors in development, R7128 is active against multiple HCV genotype...
Virologic in Medical Dictionary
...gdong Province in ... SARS — Comprehensive overview covers symptoms, causes, treatment and prevention of this respiratory illness. ... and virologic
features of SARS -CoV. ... SARS — Comprehensive overview covers symptoms, causes, treatment and prevention of this respiratory illness. ....
Virologic in Biological News
Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
...irenz were more likely to adhere to treatment and less likely to experience virologic
failure and death compared to patients taking nevirapine. Nevirapine is the...ernational Health. "Patients started on nevirapine had an increased risk of virologic
failure and death, were significantly less likely than those started on efa...
BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients
... -015, -022, -027, -026 and -901 who experienced a virologic
breakthrough1 or whose virus had not yet reached u...reatment gap of less than or equal to 35 days.
breakthrough is defined as a greater than or equal..., 43 percent of lamivudine-refractory patients had virologic
breakthrough with BARACLUDE resistance (n=33).
454 sequencing identifies HIV drug resistance at early stage
... in the US comparing three different approaches to antiretroviral therapy. The FIRST study, which lasted 5 years, evaluated the long-term clinical and virologic
effects of three initial antiretroviral drug regimens for treatment naïve HIV-infected persons. The CPCRA Statistical Center at the University of Minn...
New human retrovirus originated in mice
... culture, the major question is whether such infection could ever happen in nature.
"So, one of the things that is important about our study from a virologic
point of view, is that this is the first really solid example of an authentic xenotropic retroviral infection in a human being," said Ganem.
Cyclosporine inhibits hepatitis C virus in vitro
...s problem, patients with hepatitis C often undergo interferon-ribavirin combination therapy after receiving a liver transplant in hopes of a sustained virologic
response. At the same time, of course, the patients must take immunosuppressive agents to guard against transplant rejection.
The most commonly us...
Viral 'fitness' explains different resistance patterns to aids drugs
...mong patients who took the pills as directed.
"We believe that when new drug classes are developed, more attention should be given in defining how virologic
fitness determines how different patterns of taking medications may lead to resistance" said Steven Deeks, MD, associate professor of medicine at UCSF...
Virologic in Biological Technology
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
...e November 3, 2009
Response (RVR) data from Phase 2b
(12-week regimen) Q1 2010
Schering-Plough Reports Financial Results for 2009 Second Quarter
...ing that boceprevir, an oral hepatitis C protease inhibitor, in combination with peginterferon alfa-2b and ribavirin significantly increased sustained virologic
response compared to current standard of care. (Announced April 23)
Announced changes to the company's global collaboration with Novartis for ...
Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
... in the study will receive 800-mg daily oral ribavirin. The total duration of treatment will be 24 weeks. The primary efficacy endpoint is sustained virologic
response (SVR) at Week 48 (24 weeks following the end of treatment).
About Human Genome Sciences
The mission of HGS is to apply great sci...
Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
...5 mg/kg and 30 mg/kg vs. ribavirin 800-1400 mg/day. Throughout the 72-week trial, all doses of taribavirin demonstrated comparable efficacy (sustained virologic
response (SVR)) to ribavirin with consistently lower levels of anemia. In addition, relapse rates in the 25 mg/kg and 30 mg/kg arms were comparable w...
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
...nced patients with genotype 1 HCV infection who have been previously treated with pegylated interferon plus ribavirin, but did not achieve a sustained virologic
Cohort F consists of null responder HCV patients with genotype 1 infection who have been treated with pegylated interferon plus ...
Virco Lab, Inc. Enters Into Collaboration with SmartGene, Inc. Enhancing HIV Resistance Test Services for Laboratories and Physicians
...o be used when changing a patient's regimen due to virologic
failure or when treatment response is incomplete. ...s detectable while on therapy.(1)
In cases of virologic
failure, DHHS guidelines recommend consideration o... Accessed 04/14/2009 (page 53, Assessment of virologic
It is emph...
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
...Safety of ITMN-191 in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus (HCV).
Incidence of virologic
Escape Observed During ITMN-191 Monotherapy is Genotype Dependent, Associated with a Specific NS3 Substitution, and Suppressed Upon Combination with P...
INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
...viral Activity with a Nucleoside Polymerase Inhibitor (R7128) and Protease (R7227/ITMN-191) Inhibitor Combination in HCV: Safety, Pharmacokinetics and virologic
Results from INFORM-1 ." Information on the INFORM-1 study design and dosing is available on www.clinicaltrials.gov .
Dan Welch, Chairman, Ch...
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
...tance. In phase II clinical trials, the addition of nitazoxanide to peginterferon alfa-2a with or without ribavirin significantly increased sustained virologic
response rates in patients with chronic hepatitis C infected with HCV genotype 4. Phase II clinical trials are ongoing in the United States in patien...
Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
...eks (48 weeks for the placebo arm).
response rates are as follows: for the low and high-dose nitazoxanide arms, rapid virologic
response (RVR, HCV RNA<12 IU/mL after 4 weeks o...red with 50% for the placebo group; complete early virologic
response (cEVR, HCV RNA<12 IU/mL after 12 weeks...